DNL 343
Alternative Names: DNL-343Latest Information Update: 06 May 2024
At a glance
- Originator Denali Therapeutics Inc
- Class Acetamides; Antidementias; Cyclobutanes; Ethers; Oxadiazoles; Small molecules
- Mechanism of Action Eukaryotic-initiation-factor-2b-stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Amyotrophic lateral sclerosis
- Preclinical Ataxia
- No development reported Dementia; Unspecified
Most Recent Events
- 01 May 2024 Denali Therapeutics completes enrolment in the Phase-II/III HEALEY ALS Platform trial for Amyotrophic lateral sclerosis in USA (NCT05842941) ,
- 28 Mar 2024 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in New Zealand (PO)
- 01 Mar 2024 Denali Therapeutics initiates a phase I pharmacokinetic trial (In volunteers) in USA (PO) (NCT06281158)